Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
News about coronavirus in Florida and around the world is constantly emerging. It's hard to stay on top of it all but Health News Florida can help. Our responsibility is to keep you informed, and to help discern what’s important for your family as you make what could be life-saving decisions.

Are the new boosters that target omicron better than the previous shots?

A Jackson, Miss., resident receives a Pfizer booster shot from a nurse at a vaccination site Feb. 8.
Rogelio V. Solis
/
AP
Only about 20 million people have, even though more than 200 million have been eligible since Labor Day.

Even if the boosters aren't any better than the original vaccine, health experts say they should be effective at helping restore some of the immunity that has faded since people got their last shots or infections.

President Joe Biden rolled up his sleeve in front of reporters at the White House on Tuesday to get one of the new COVID-19 bivalent boosters. The event was part of the administration's campaign to encourage more people to get one of the shots before another possible surge.

The vaccines are the first to target the omicron variant and are being promoted as providing better protection than the original shots. But are they more effective? Two recent studies, the first with direct data from people, suggested the vaccines may work as well as the original but are not superior.

To save time, emergency use authorizations for these mRNA boosters from Moderna and Pfizer- BioNTech were based on how well the shots stimulated the immune system and on tests on mice.

So, researchers at Columbia and Harvard compared how the immune systems of volunteers responded.

About a month after being injected, the new boosters did not stimulate significantly higher levels of antibodies that could neutralize the BA.4 and BA.5 subvariants currently infecting most people.

“To disappointment, the bivalent vaccine did not show superiority over the original vaccine,” says Dr. David Ho, a professor of microbiology and immunology at Columbia.

The results follow announcements this month from Moderna and Pfizer-BioNTech suggesting the boosters would provide better protection.

Even if the boosters aren't any better than the original, health experts say they should be just as effective at helping restore some of the immunity that has faded since people got their last shots or infections. That could be lifesaving, especially for those who are most vulnerable, like the elderly.

Deepta Bhattacharya, a professor of immunobiology at the University of Arizona, says the new studies were too small and too short to reach any firm conclusions. Larger studies will be needed.

“For those who are saying, see, see, I told you so, I would say, let's stand down a little bit and wait for some cleaner data to come out because these studies can't be used to support, really, one argument or another,” Bhattacharya says.

Might larger and longer studies could show the boosters provide longer-lasting immunity or even help people fight off new variants? Immunologist John Wherry at the University of Pennsylvania says people have to be realistic.

“It's a little bit of a - sort of a reality check or a reset that the bivalent vaccines are not a magic bullet. They're not going to give us, you know, perfect protection from these new omicron variants that are circulating,” says Wherry.

Biden’s event on Tuesday was staged in hope of getting more people to receive the booster. Only about 20 million people have, even though more than 200 million have been eligible since Labor Day.

Rob Stein is a correspondent and senior editor on NPR's science desk.
Erika Ryan
Erika Ryan is a producer for All Things Considered. She joined NPR after spending 4 years at CNN, where she worked for various shows and CNN.com in Atlanta and Washington, D.C. Ryan began her career in journalism as a print reporter covering arts and culture. She's a graduate of the University of South Carolina, and currently lives in Washington, D.C., with her dog, Millie.
Scott Hensley edits stories about health, biomedical research and pharmaceuticals for NPR's Science desk. During the COVID-19 pandemic, he has led the desk's reporting on the development of vaccines against the coronavirus.
Juana Summers is a political correspondent for NPR covering race, justice and politics. She has covered politics since 2010 for publications including Politico, CNN and The Associated Press. She got her start in public radio at KBIA in Columbia, Mo., and also previously covered Congress for NPR.